Clinical trials: System; Sclerosis
Raynaud Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
This is a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to evaluate the effect of iloprost on the symptomatic relief of Raynaud's Phenomenon attacks in subjects with symptomatic Raynaud's Phenomenon…
- Trial name
- NCT03867097
- Testing
- Iloprost Injection, for intravenous use
- Where
- 16 sites in United States
- Volunteers
- 34 people
- Sponsor
- Civi Biopharma, Inc.
Multiple Sclerosis
Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series
This study evaluates the effectiveness of personalized physical activity coaching combined with the use of a physical activity monitor to support increased levels of daily physical activity in individuals with multiple sclerosis.
- Trial name
- NCT02335450
- Testing
- Motivational Interviewing, Wristband physical activity monitor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oakland University
Multiple Sclerosis
ATX-MS-1467 in Multiple Sclerosis
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of…
- Trial name
- NCT01973491
- Testing
- ATX-MS-1467
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Cognitive Decline
Digital Cognition in Multiple Sclerosis
A DIGITAL THERAPEUTIC TO IMPROVE THINKING IN MULTIPLE SCLEROSIS WHO: 65 participants with a confirmed diagnosis of Multiple Sclerosis (MS) WHY: Purpose of the study is to compare the effect of 2 tablet-based brain training…
- Trial name
- DigCog (NCT03569618)
- Testing
- Tablet-based Game
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of California, San Francisco
Amyotrophic Lateral Sclerosis (ALS)
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS patients and assess preliminary indications of efficacy
- Trial name
- ALS (NCT03580616)
- Testing
- L-Serine
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Elijah W. Stommel
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Pediatric Onset Multiple Sclerosis (POMS)
Impact of Physical Activity on Cognitive Outcomes in Youth With Pediatric-Onset Multiple Sclerosis (POMS)
The purpose of this study is to to determine how implementing a home-based virtual reality video (VR) game exercise program in young people with Multiple Sclerosis(MS) can improve disability outcomes by measuring its impact on…
- Trial name
- NCT03933020
- Testing
- VR active video game intervention, Educational session, Standard Management of Physical Activity
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- The University of Texas Health Science Center, Houston